Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1601
Associated Banc-Corp
ASB
$6.07B
| $11.3M | ﹤0.01% |
438,484
+33,297
| +8% | +$856K |
|
1602
Webster Financial
WBS
$12.8B
| $11.3M | ﹤0.01% |
178,883
+13,800
| +8% | +$819K |
|
1603
MaxLinear
MXL
$6.95B
| $11.2M | ﹤0.01% |
644,370
+3,379
| +0.5% | +$55K |
|
1604
Mirum Pharmaceuticals
MIRM
$6.02B
| $11.2M | ﹤0.01% |
142,144
+26,373
| +23% | +$1.89M |
|
1605
CALL
3M
MMM
$94.2B
| $11.2M | ﹤0.01% |
70,000
-171,300
| -71% | -$28M |
|
1606
Southwest Gas
SWX
$6.67B
| $11.2M | ﹤0.01% |
139,846
-9,331
| -6% | -$747K |
|
1607
Texas Capital Bancshares
TCBI
$4.38B
| $11.2M | ﹤0.01% |
123,539
-2,115
| -2% | -$186K |
|
|
DAY
1608
DELISTED
Dayforce
DAY
| $11.2M | ﹤0.01% |
161,546
-121,440
| -43% | -$8.36M |
|
1609
Aramark
ARMK
$16.1B
| $11.2M | ﹤0.01% |
302,838
-140,898
| -32% | -$5.37M |
|
1610
Zurn Elkay Water Solutions
ZWS
$8.41B
| $11.1M | ﹤0.01% |
239,713
+18,259
| +8% | +$857K |
|
1611
New Jersey Resources
NJR
$5.64B
| $11.1M | ﹤0.01% |
240,887
-60,276
| -20% | -$2.79M |
|
1612
Liberty Broadband Class C
LBRDK
$5.29B
| $11.1M | ﹤0.01% |
228,527
+16,682
| +8% | +$868K |
|
1613
Scholar Rock
SRRK
$6.46B
| $11.1M | ﹤0.01% |
251,913
-92,771
| -27% | -$3.48M |
|
1614
Avantor
AVTR
$9.37B
| $11.1M | ﹤0.01% |
967,555
-149,603
| -13% | -$1.84M |
|
1615
CNO Financial Group
CNO
$5.07B
| $11M | ﹤0.01% |
259,949
-98
| -0% | -$3.99K |
|
1616
Trip.com Group
TCOM
$28.3B
| $11M | ﹤0.01% |
153,377
+35,248
| +30% | +$2.52M |
|
1617
Selective Insurance
SIGI
$5.59B
| $11M | ﹤0.01% |
131,670
-8,653
| -6% | -$694K |
|
1618
Floor & Decor
FND
$6.27B
| $11M | ﹤0.01% |
180,044
-335,699
| -65% | -$21.8M |
|
1619
PUT
Alaska Air
ALK
$5.3B
| $10.9M | ﹤0.01% |
217,500
+67,500
| +45% | +$3.12M |
|
1620
Kymera Therapeutics
KYMR
$9.51B
| $10.9M | ﹤0.01% |
140,507
-14,637
| -9% | -$988K |
|
1621
Mercury Systems
MRCY
$6.59B
| $10.9M | ﹤0.01% |
149,172
+2,301
| +2% | +$171K |
|
1622
Strategic Education
STRA
$1.86B
| $10.9M | ﹤0.01% |
135,445
+12,380
| +10% | +$989K |
|
1623
Revolution Medicines
RVMD
$43.3B
| $10.8M | ﹤0.01% |
136,048
-154,401
| -53% | -$10.1M |
|
|
ECG
1624
Everus Construction Group
ECG
$7.02B
| $10.8M | ﹤0.01% |
126,387
+40,482
| +47% | +$3.62M |
|
1625
CALL
ARK Innovation ETF
ARKK
$6.54B
| $10.8M | ﹤0.01% |
+140,000
| New | +$11.6M |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.